EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

Ilse A C Spiekman, Niven Mehra, Laurien J Zeverijn, Birgit S Geurts, Karlijn Verkerk, Soemeya F Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W J de Leng, Anne M L Jansen, Addy C M van de Luijtgaarden, Theo van Voorthuizen und 4 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70191 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Ilse A C Spiekman und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Neoplasms, Recombinational DNA Repair. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stelvio for Life Foundation, KWF Kankerbestrijding, Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRCA1/2 are crucial in the homologous recombination repair (HRR) pathway, with loss‐of‐function (LoF) alterations predicting sensitivity to PARP‐inhibitors (PARPi). Whether other HRR‐gene alterations confer PARPi sensitivity remains unclear. In the Drug Rediscovery Protocol, patients receive off‐label drugs matched to their tumor molecular profile. Here, olaparib efficacy and safety were evaluated in adult patients with treatment‐refractory, progressive malignancies harboring LoF alterations in ATM (cohort A) or other HRR‐genes including CDK12 , PPP2R2A , CHEK1/2 , and RAD51B (cohort B). Primary endpoints were clinical benefit (CB: confirmed objective response or stable disease ≥16 weeks) and safety. Pre‐treatment biopsies were analyzed by whole‐genome sequencing (WGS) for target validation. CB was observed in 8/25 patients (32%) in cohort A (prostate cancer: n = 6, adenoid cystic carcinoma: n = 1, endometrial cancer: n = 1). No effectiveness was seen in patients with colorectal cancer ( n = 8). Median progression‐free survival (PFS) and overall survival (OS) were 3.4 months (95% CI 1.8–5.3) and 9.2 months (95% CI 5.2–21.3), respectively. In cohort B, the CB rate was 41.7% (10/24) with median PFS and OS of 3.5 months (95% CI 3.4–6.6) and 8.1 months (95% CI 6.6–14.2), respectively. CB was observed in CKD12 ( n = 7), RAD51B ( n = 2), and CHEK2 ‐altered tumors ( n = 1), but not in PPP2R2A ( n = 6) or CHEK1 ‐altered tumors ( n = 1). No unexpected toxicities occurred. WGS confirmed inclusion target in 84% of tested patients. In conclusion, PARPi sensitivity varies across HRR‐genes, indicating that relying solely on an altered common mechanistic pathway is insufficient to predict response. Future studies should target specific HRR‐genes to assess subgroup‐specific benefits and determine proper use of molecular diagnostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesPiperazinesNeoplasmsRecombinational DNA RepairPoly(ADP-ribose) Polymerase InhibitorsHumansFemaleMaleMiddle AgedAgedAdult

Stichwörter der Autor:innen

DRUP‐trialHRRPARPiolaparibprecision medicine

Substanzen

olaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
  • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Hartwig Medical Foundation, Amsterdam, the Netherlands.

ORCID-Profile: Tineke E Buffart, Emile E Voest, Henk M W Verheul

Förderung

  • Stelvio for Life Foundation
  • KWF Kankerbestrijding
  • Amgen
  • AstraZeneca
  • GlaxoSmithKline
  • Incyte
  • Janssen
  • Eli Lilly

Zitieren

APA

Spiekman, I. A. C., Mehra, N., Zeverijn, L. J., Geurts, B. S., Verkerk, K., Haj Mohammad, S. F., van der Noort, V., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., van de Luijtgaarden, A. C. M., van Voorthuizen, T., Buffart, T. E., Gelderblom, H., Voest, E. E., & Verheul, H. M. W. (2026). Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol. International Journal of Cancer. https://doi.org/10.1002/ijc.70191

Vancouver

Spiekman IAC, Mehra N, Zeverijn LJ, Geurts BS, Verkerk K, Haj Mohammad SF, et al. Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol. International Journal of Cancer. 2026. doi:10.1002/ijc.70191

BibTeX
@article{Spiekman2026,
  author = {Spiekman, Ilse A C and Mehra, Niven and Zeverijn, Laurien J and Geurts, Birgit S and Verkerk, Karlijn and Haj Mohammad, Soemeya F and van der Noort, Vincent and Roepman, Paul and de Leng, Wendy W J and Jansen, Anne M L and van de Luijtgaarden, Addy C M and van Voorthuizen, Theo and Buffart, Tineke E and Gelderblom, Hans and Voest, Emile E and Verheul, Henk M W},
  title = {Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70191}
}
Kostenlos starten →